Revolutionizing AAV Delivery Platforms: Minimizing Immunogenicity & Maximizing Biodistribution for Enhanced Brain Targeting
Time: 2:05 pm
day: Pre-Conference 1 Track PM
Details:
Despite notable promising efforts to achieve brain-wide transduction in mice and monkeys, developing a BBB-crossing capsid remains an unsolved problem.
• How can we translate successful cases of AAV delivery in vivo into clinical programs and overcome challenges of cross species differences in capsid property requirements?
• Which features of capsid design should be improved to enhance BBB penetration efficiency and frequency of neuronal uptake?
• How do we establish a successful balance between sufficient dose levels and peripheral immunogenicity?
